Natixis’s Avalo Therapeutics AVTX Stock Holding History

Natixis’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,512	Closed	-$54.6K	–	1004
2024 Q1	$54.6K	Sell	2,512 -2,092	-45%	-$11.3K	﹤0.01%	821
2023 Q4	$43.3K	Buy	+4,604	New	+$104K	﹤0.01%	840

Other funds holding AVTX

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Natixis's AVTX Position: Q2 2024 in Review

Natixis sold out of Avalo Therapeutics (AVTX) in Q2 2024, closing a stake of 2,512 shares — an estimated $54.6K sold.

Natixis first reported a position in AVTX in Q4 2023 and held it in 2 quarters. The position peaked at $54.6K in Q1 2024. 21 funds tracked by Wall St. Rank hold AVTX as of Q2 2024.

Natixis reported no remaining Avalo Therapeutics position as of Q2 2024 after selling out during the quarter.
Natixis sold 2,512 Avalo Therapeutics shares in Q2 2024, an estimated $54.6K.
Natixis first reported a position in Avalo Therapeutics in Q4 2023 and held it in 2 quarters.
Natixis's Avalo Therapeutics position peaked at $54.6K in Q1 2024.
21 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2024.

Based on Natixis's 13F filing for Q2 2024, filed 13 Aug 2024.